InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Tiziana Life Sciences Ltd

TLSA Clue Score34
United Kingdom Fiscal year ends December CIK 0001723069
$1.19 +5.31% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.19 −17.93% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 20 Nov 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2016Operating income−9.9Net income−9.8Fiscal year 2017Operating income−10.5Net income−8.6Fiscal year 2018Operating income−9.9Net income−7.9Fiscal year 2019Operating income−9.9Net income−9.3Fiscal year 2020Operating income−28.0Net income−26.1EPS, diluted−0.16Fiscal year 2021Operating income−27.4Net income−23.4EPS, diluted−0.24Fiscal year 2022Operating income−14.6Net income−15.4EPS, diluted−0.15Fiscal year 2023Operating income−18.0Net income−17.7EPS, diluted−0.17Fiscal year 2024Operating income−15.8Net income−11.9EPS, diluted−0.11
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Operating income −9.9 −10.5 −9.9 −9.9 −28.0 −27.4 −14.6 −18.0 −15.8
Net income −9.8 −8.6 −7.9 −9.3 −26.1 −23.4 −15.4 −17.7 −11.9
Growth
EPS, diluted n/a n/a n/a n/a −0.16 −0.24 −0.15 −0.17 −0.11
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Capital expenditure−0.0Fiscal year 2017Operating cash flow−7.5Capital expenditure−0.0Free cash flow−7.5Fiscal year 2018Operating cash flow−4.6Fiscal year 2019Operating cash flow−6.8Capital expenditure−0.0Free cash flow−6.8Fiscal year 2020Operating cash flow−11.3Capital expenditure−0.0Free cash flow−11.3Fiscal year 2021Operating cash flow−21.8Capital expenditure−0.0Free cash flow−21.8Fiscal year 2022Operating cash flow−19.6Fiscal year 2023Operating cash flow−15.7Fiscal year 2024Operating cash flow−1.5Capital expenditure−0.0Free cash flow−1.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Operating cash flow n/a −7.5 −4.6 −6.8 −11.3 −21.8 −19.6 −15.7 −1.5
Capital expenditure −0.0 −0.0 n/a −0.0 −0.0 −0.0 n/a n/a −0.0
Free cash flow n/a −7.5 n/a −6.8 −11.3 −21.8 n/a n/a −1.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash5.8Shareholders’ equity4.1Fiscal year 2017Cash0.1Shareholders’ equity−2.3Fiscal year 2018Cash5.3Shareholders’ equity75.8Fiscal year 2019Cash0.2Shareholders’ equity69.6Fiscal year 2020Cash65.8Shareholders’ equity62.4Fiscal year 2021Cash42.2Shareholders’ equity41.3Fiscal year 2022Cash18.1Shareholders’ equity19.6Fiscal year 2023Cash1.2Shareholders’ equity5.5Fiscal year 2024Cash3.7Shareholders’ equity3.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Cash 5.8 0.1 5.3 0.2 65.8 42.2 18.1 1.2 3.7
Shareholders’ equity 4.1 −2.3 75.8 69.6 62.4 41.3 19.6 5.5 3.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2024 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024
Returns
−239.0% n/a −10.5% −13.4% −41.9% −56.7% −78.7% −319.6% −301.4%
n/a −347.8% −114.7% −392.1% −37.0% −48.0% −58.2% −145.2% −105.1%
Balance and payout
n/a 192.2% 92.5% 331.9% 11.7% 15.5% 26.1% 54.6% 65.1%